Adam Bryant
CEO, CanSense


CanSense is developing a fast, inexpensive and scalable test for the early diagnosis of bowel cancer using artificial intelligence-based modelling (AI).  The test is a potential game changer in the approach to bowel cancer diagnosis and screening.  It is focused on patient acceptability and reduced mortality via early stage diagnosis. It has the additional benefit of reducing the demands on more invasive colonoscopy diagnosis and reducing the financial burden on the healthcare provider.

Matchmaking Information

Processing. Please wait.